Overview of Soneryl

Property	Description
Active ingredient	Butobarbital (Butobarbitone)
Form	Oral tablet
Pharmacological class	Barbiturate, Central Nervous System (CNS) depressant
General purpose	Sedation, Induction of sleepiness
Origin	Synthetic substance

What Type of Medicine is Soneryl?

Soneryl is a medicinal product containing the active ingredient Butobarbital (Butobarbitone), a synthetic substance classified as a potent Central Nervous System (CNS) depressant. This medication fundamentally belongs to the barbiturate pharmacological class, an established group of drugs that modulate brain activity, reflecting its sedative-hypnotic properties. As an intermediate-acting barbiturate, it is characterized by its ability to induce sleep.

Within its class, Butobarbital is specifically identified as an intermediate-acting compound, which defines its sustained physiological action on the nervous system. The core purpose of this single-ingredient product is derived entirely from the properties of Butobarbital, aligning its function with that of hypnotics and sedatives. Historically, Soneryl was commercially recognized as a prescription-only medicine specifically positioned for adult patients requiring powerful and reliable sedation.

Composition, Form, and General Purpose

Soneryl is supplied primarily as an oral tablet, which is the dosage form designed for oral administration and composed of Butobarbital combined with standard solid pharmaceutical excipients as the base/vehicle.

The medication's general purpose is directly linked to its high-level mechanism of effect, which involves enhancing inhibitory GABAergic tone—the brain's natural signal to slow down. By potentiating the action of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, Butobarbital achieves a comprehensive depression of the Central Nervous System. This action leads to the induction of sleepiness and deep sedation, making it a therapeutic tool for managing conditions that require substantial central neural calming. This classification reflects the drug's primary action, which is to slow down activity in the central nervous system.

What side effects are possible with Soneryl?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Soneryl (Butobarbital) as classified in regulatory documents. This information focuses strictly on the safety profile and is not clinical advice.

Adverse Reaction Classifications

The most frequently classified adverse effect of this Central Nervous System (CNS) depressant is somnolence (drowsiness), which is officially listed as Common (occurring in 1% to 10% of users). Other officially documented, though Rare, effects include constipation, nervousness, nightmares, and headache. Adverse reactions are grouped by the affected system, including the Nervous System (e.g., dizziness, ataxia), Psychiatric Disorders (e.g., confusion, anxiety), Gastrointestinal Disorders, and Respiratory function (e.g., respiratory depression).

Serious Safety Risks

Regulatory labeling highlights specific serious adverse reactions. These include Anaphylaxis and Angioedema (severe, life-threatening allergic reactions), and the risk of Severe Respiratory Depression. A critical safety concern documented in official sources is the potential for Complex Sleep-Related Behaviors, such as sleep-driving, which may occur with no memory of the event.

Dependence and Withdrawal: Butobarbital is classified as habit-forming. Prolonged use is associated with developing Tolerance and Physical Dependence. Abrupt cessation after chronic use can lead to severe withdrawal symptoms, including convulsions and delirium, as detailed in regulatory documents.

Population and Usage Restrictions

Official safety statements advise that Older Adults may be more sensitive to the effects and face a higher risk of adverse reactions such as marked excitement, confusion, and falls. The medicine is Contraindicated (must not be used) in individuals with a history of manifest or latent porphyria. Furthermore, the regulatory profile advises caution concerning its use during Pregnancy due to the potential for fetal damage.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of the active ingredient, Butobarbital (Butobarbitone), is recognized in regulatory documents as a serious event potentially leading to life-threatening outcomes. As a potent Central Nervous System (CNS) depressant, overexposure results in a progression of symptoms from severe drowsiness, slurred speech, and poor coordination to deep coma and loss of consciousness.

Life-Threatening Manifestations

The most critical documented complications involve the cardiorespiratory systems. These include life-threatening respiratory depression, which can progress to apnea (cessation of breathing), and cardiovascular collapse, evidenced by severe hypotension (low blood pressure) and shock. Regulatory labeling notes that overdose can produce death.

Emergency Actions and Management

Official government guidance mandates that any suspected overdose requires immediately seeking emergency medical attention or calling emergency services at once. Specific life-threatening signs, such as trouble breathing, inability to be awakened, or collapse, require urgent help. No specific antidote is known for Butobarbital. Management is therefore confined to symptomatic and supportive treatment, including meticulous monitoring of vital signs, mechanical support for breathing, and measures to maintain circulation.

Population-Specific Risks

Labeling notes that elderly or debilitated patients and children who accidentally ingest even a single dose are at heightened risk for severe outcomes.

Therapeutic Uses of Soneryl

What Soneryl treats: Main Uses and Benefits

Soneryl is commonly used across therapeutic domains involving certain distressing symptoms, applicable in contexts with acute or disruptive symptom patterns. The medication is utilized for its sedative and hypnotic properties. This medication is generally applied in addressing conditions marked by increased discomfort or tension or sleep disturbances, including acute insomnia, difficulty falling asleep, and the need for preoperative sedation.

Therapeutic Domains and Benefits

This medication is applied in addressing symptom clusters related to acute sleep disturbance, generally managing symptoms like profound difficulty falling asleep and frequent nocturnal awakenings. The key therapeutic benefit contributes to the induction of sleep and may assist with managing symptoms that interfere with sleep continuity, which provides support that helps ease the overall symptom load and supports rest during periods of heightened symptoms.

For patients facing procedures, Soneryl is considered relevant for providing preoperative sedation, assisting in addressing symptoms of intense apprehension and tension relevant when supportive symptom management is appropriate. In situations requiring profound calming, the medicine is used for managing symptoms of heightened physiological activity and general excitation, including profound restlessness. It provides supportive relief when symptoms become temporarily overwhelming, which may contribute to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Tension The medication is relevant when symptoms related to general excitation or severe sleeplessness become noticeable, offering support for improved rest and necessary calming.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Soneryl (Butabarbital)

Official regulatory documents establish specific populations for whom the use of Soneryl is strictly prohibited or requires special consideration. This medicine is contraindicated (must not be used) in patients with the following conditions:

Hypersensitivity: Known allergy or sensitivity to butabarbital, the active ingredient, or any other drug belonging to the barbiturate class.
Porphyria: A history of manifest (active) or latent (inactive/hidden) porphyria, which is an enzyme disorder.
Severe Hepatic Impairment: Severe liver disease or failure, including the presence of premonitory signs of hepatic coma.

Use in Specific Populations

Special caution is necessary, and use may be limited or require reduced doses, for the following groups:

Population Group	Eligibility Status/Restriction
Elderly/Debilitated	Use with caution; may require a reduced initial dose due to increased sensitivity to the drug's effects.
Liver Damage (General)	Use with caution and a reduced initial dose.
Kidney Disease	Use with caution as slower removal of the drug from the body may increase its effects.
Pregnancy/Lactation	Caution is advised during breastfeeding as the drug is excreted into human milk. Use during pregnancy may cause fetal harm and is generally not recommended.
Pediatric Use	Established for preoperative sedation; safety and efficacy are not established for treating insomnia in children.

Some formulations contain FD&C Yellow No. 5 (tartrazine), which may cause allergic reactions, especially in individuals with aspirin hypersensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Soneryl, which contains the active ingredient Butobarbital (a barbiturate), is defined by its two primary pharmacological interaction patterns: potent Central Nervous System (CNS) depression and hepatic enzyme induction. These patterns establish formal restrictions and the classification of clinically significant drug-drug combinations.

Pharmacodynamic Interactions (CNS Depression)

Co-administration with other potent CNS depressants is strictly documented as resulting in additive effects. This includes medicines such as opioid analgesics, benzodiazepines, and other sedatives. The combination with alcohol (ethanol) is also restricted due to the established risk of potentiating CNS depressant effects.

Pharmacokinetic Interactions (Enzyme Induction)

Butobarbital is documented to be a potent inducer of hepatic microsomal enzymes (CYP system). This induction increases the metabolism of several co-administered medicines, leading to reduced plasma concentrations and potentially diminished therapeutic effect. This interaction applies to substances such as oral anticoagulants (e.g., Warfarin) and oral contraceptives.

Formal Restrictions and Population Notes

Use is formally contraindicated with certain medicines, including the antifungal Voriconazole, due to the risk of substantially reduced exposure leading to treatment failure. The regulatory profile notes that interactions resulting in CNS depression may be more severe for elderly or debilitated patients. Additionally, use is restricted in specific medical conditions, including severe hepatic impairment and porphyria, due to altered drug clearance and known disease risks.

Mechanism of Action

Molecular Modulation of the GABA A Receptor

Butobarbital is a positive allosteric modulator of the GABA A receptor complex, the primary inhibitory neurotransmitter receptor in the brain. The molecule binds to a specific site on the receptor, leading to a prolongation of the Cl^- ion channel open time. This increased duration of negative chloride ion flow results in the hyperpolarization of the neuronal membrane, making the cell less excitable.

Mechanism of Generalized CNS Depression

The widespread cellular inhibition cascades into a broad suppression of electrical activity across the central nervous system (CNS). This mechanism primarily acts by depressing the Ascending Reticular Activating System (ARAS), the key pathway responsible for maintaining alertness and consciousness. This systemic slowing of neural activity is the direct physiological change that results in generalized CNS depression, a state characterized by reduced arousal and neural function.

Functional Limits of Barbiturate Action

The non-selective nature of the generalized CNS depression mechanism carries inherent physiological constraints. At high concentrations, the drug's shift to direct GABA A agonism can severely depress vital brainstem centers controlling autonomous functions, illustrating a functional boundary where the mechanism results in a suppression of necessary homeostatic reflexes.

Dosage and Administration Information

The administration of Soneryl (Butobarbital) follows the oral route for intake, typically as a tablet. Usage is limited to a short duration, such as a maximum of two weeks for the management of insomnia, consistent with the parameters for its use.

Labeled Dosing Regimens

Usage is guided by the specific clinical context, necessitating different schedules for sedation versus sleep induction. The recommended application for hypnotic use involves short-term administration and gradual withdrawal (tapering) upon cessation.

Indication	Standard Adult Dose	Frequency and Timing
Daytime Sedation	15 mg to 30 mg	3 or 4 times daily
Short-Term Hypnotic	50 mg to 100 mg	Once daily at bedtime
Preoperative Use	50 mg to 100 mg	Single dose 60 to 90 minutes prior to procedure

Specific Administration Instructions

For the hypnotic regimen, the dose is typically taken just prior to retiring and preferably on an empty stomach to ensure a timely onset of action.

Special attention is paid to dosing for certain populations. The initial dose is typically lower for older or debilitated adults, and dose modification is also necessary for patients with hepatic impairment because of the body’s reliance on liver metabolism for clearance. Dosing for preoperative use in children follows a weight-based regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Soneryl

This section provides an overview of the clinical research and evidence structure for Butobarbital (Soneryl), based only on authoritative regulatory and scientific documentation. This information is intended to describe what has been observed in studies, not to provide treatment advice.

Evidence for Use in Acute Sleep Disturbance (Hypnotic Use)

Research exploring how symptoms change over time for acute sleep disturbance primarily relies on early Randomized Controlled Trials (RCTs) and comparative clinical trials. These studies were designed to evaluate Butobarbital's profile against a placebo (an inactive substance) or other compounds that were being studied. The studies explored outcomes related to physical discomfort and systemic imbalance, focusing on measures of sleep, particularly for individuals experiencing conditions involving periods of heightened symptoms, such as difficulty falling asleep.

Findings describe patterns observed in the studies where Butobarbital was studied for and was observed in trials to explore outcomes related to the initial phase of sleep. Research highlights measurements taken during the study period; studies documented a shorter time until participants fell asleep in the observed groups. However, the evidence also contributes to understanding symptom patterns, particularly the observed data that the measurements taken may not be sustained.

Evidence for Use in Preoperative Sedation

Research for the use of Soneryl in settings involving calming before a medical procedure is derived from clinical trials and observational data collected during periods of increased symptom activity, such as the time leading up to surgery. Studies monitored outcomes capturing phases of heightened symptom activity, particularly pre-procedure apprehension and tension.

Studies report how symptoms evolved in the observed populations, and the data show patterns related to a rapid onset of changes measured as sedation after administration. Research describes its use for the assessment of apprehension, which was monitored via subjective assessment scales in the periprocedural setting. Findings indicate that this type of sedation was monitored during the preparation needed before general anesthesia.

What Remains Uncertain About Soneryl

Long-term effects are not fully established, and evidence quality varies across studies due to the age of the research. The primary regulatory observation documented in the research is the potential for tolerance, where the initial measured change may weaken after two weeks of continuous use. Comparative evidence is lacking against newer medications developed since those studies were conducted. Furthermore, there is insufficient evidence to fully describe study outcomes in older adult populations or those with complex health profiles.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Soneryl (FAQ)

Q: Why is Soneryl sometimes prescribed for purposes other than sleep?

A: Official documents indicate that Soneryl, which contains Butobarbital, is approved for several uses beyond the short-term treatment of insomnia. The approved indications also include its use for daytime sedation and for preoperative sedation (calming before a medical procedure). Regulatory documents only describe these specific approved uses.

Q: Do experts recommend Soneryl for short-term or long-term use?

A: The drug is officially classified for short-term use only. Official guidance for insomnia treatment is limited to a maximum duration of approximately two weeks. Evidence indicates that the drug’s effectiveness may diminish after this period, and its use is therefore limited to short durations in official guidance.

Q: Is there a maximum length of time Soneryl should be used, according to official sources?

A: Yes. For the short-term management of insomnia, official guidance typically limits the duration of use to a maximum of two weeks. This limitation reflects observations that the medicine's effectiveness for sleep induction may not be sustained beyond this brief period.

Q: Does Soneryl lose its effectiveness over time?

A: Official patient information notes that the body can develop tolerance to the drug's effects. This means the medicine typically loses its effectiveness for sleep induction and maintenance after approximately two weeks of continuous use, which aligns with the short-term use mandate.

Q: Is it possible to develop a tolerance to Soneryl?

A: Yes. Regulatory information confirms that the body can develop tolerance to the effects of the active ingredient, Butobarbital. This tolerance is the reason why the drug's effectiveness for sleep induction often diminishes after a few weeks of continuous use.

Q: Is it common to feel groggy the morning after taking Soneryl?

A: Regulatory patient information acknowledges that some individuals may still feel drowsy or less alert upon waking. This residual effect can occur if the full period of rest has not been completed, or if a person must wake up before the drug's effects have fully worn off.

Q: How long after taking Soneryl is it generally considered safe to wake up and function?

A: The patient guidance indicates that the medicine is intended to be taken when a person can get a full night's sleep, generally described as about 7 to 8 hours. Waking up earlier than this may result in continued drowsiness and temporary memory problems.

Q: How long does Soneryl stay in your system?

A: Butabarbital is classified as an intermediate-acting compound. Its effects typically last for a duration of approximately 6 to 8 hours after oral administration.

Q: What happens in the body when Soneryl starts to work?

A: The active ingredient acts by increasing the effect of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) in the brain. This action slows down activity in the Central Nervous System (CNS), leading to a state of reduced arousal and sedation.

Q: Are there any foods or drinks that should be avoided while taking Soneryl?

A: Official documents strictly restrict the co-administration of the medicine with alcohol (ethanol) due to the established risk of potentiating or increasing CNS depression. Official guidance also indicates that the medicine is to be taken on an empty stomach to help ensure a timely onset of action.

Q: Does Soneryl affect dream recall?

A: Official adverse event documents list nightmares as a rare side effect that has been reported. The product labeling does not describe the drug's general effect on non-disturbing dreams or overall dream recall.

Q: Can taking Soneryl affect a person's mood?

A: Official documents list various adverse effects classified as psychiatric disorders. These include reported reactions such as worsening of depression, confusion, anxiety, and instances of unusual excitement or irritability.

Q: Is it normal to have unusual thoughts while taking Soneryl?

A: Official patient information warns that individuals should report any unusual and strange thoughts or behavior to their healthcare professional. Examples listed include hallucinations and unusual excitement.

Q: Are allergic reactions to Soneryl common?

A: Regulatory warnings highlight the risk of serious allergic reactions, including anaphylaxis and angioedema, which are severe, potentially life-threatening events requiring immediate medical attention. The official labeling does not explicitly classify the frequency of general, less severe allergic reactions.

Q: Are there known effects of Soneryl on blood pressure?

A: The regulatory safety profile notes that in cases of overdose or significant intoxication, a decrease in blood pressure (hypotension) and effects on the cardiovascular system have been observed.

Q: Are there specific warnings about Soneryl use in people with a history of substance misuse?

A: Official warnings indicate that individuals with a history of alcohol or drug abuse should use the medicine with caution. This is noted because the drug's habit-forming nature carries a potential risk of worsening these existing conditions.

Q: Do regulatory bodies advise specific monitoring while taking Soneryl?

A: Official documentation advises that monitoring may be needed, especially for patients taking the medicine for longer periods. This monitoring can include periodic blood counts and liver and kidney function tests.

Q: Do studies show that Soneryl helps with chronic insomnia?

A: Regulatory documents limit the use of this drug to the short-term treatment of insomnia (typically up to two weeks). They also caution that effectiveness for sleep maintenance often diminishes after this period, limiting its established use to only short-term conditions.

Q: What kind of research has been done on the long-term effects of Soneryl?

A: Research themes related to long-term use primarily focus on the development of tolerance and physical dependence. These are key potential risks associated with the prolonged use of this pharmacological drug class.

Q: Is there a generic version of Soneryl available?

A: The active ingredient in Soneryl, Butobarbital (Butabarbital), has had generic versions approved and available from various manufacturers in the form of Butabarbital Sodium tablets.

Q: Is Soneryl available over the counter in some countries?

A: Butabarbital is generally classified as a Schedule III controlled substance in the United States and is a prescription-only medicine in major regulatory regions. This status is due to its potential for dependence and abuse. Official labeling does not certify its regulatory status in every country worldwide.

How should Soneryl be stored and disposed of?

How to Store and Dispose of Soneryl?

The storage and disposal of Soneryl (Butobarbital) must strictly adhere to the conditions documented in official regulatory labeling.

Storage Requirements

Soneryl must be stored at room temperature, specifically 20 C to 25 C (68 F to 77 F), in a closed, tightly closed container. The medication must be protected away from direct light and excess heat and moisture (such as a bathroom). It is explicitly stated that the product must not be frozen.

Child-Safety and Stability

To prevent accidental exposure, Soneryl must be kept out of the sight and reach of children at all times. Regarding product stability, official labeling instructs users to not keep outdated medicine or medicine that is no longer needed.

Disposal

For proper disposal, individuals should ask a healthcare professional how to discard any unused or expired tablets.

Soneryl